Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02023346 · ClinicalTrials.gov registry record
Prognostic Awareness and Patient-Physician Communication in Malignant Glioma
A clinical trial of Malignant Glioma, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- 95
- Enrollment target
- 1
- Study location
NCT02023346: Completed study of Malignant Glioma, sponsored by Memorial Sloan Kettering Cancer Center.
NCT02023346 is a study of Malignant Glioma that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 95 participants, roughly in line with the 90-participant average among 40 other Malignant Glioma trials with a reported enrollment target. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02023346, a study of Malignant Glioma, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- 95 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to learn more about the understanding patients with brain tumors have of their disease and their communication with their physician. Ultimately, we hope to use these findings to improve communication between patients and their doctors.
Primary Outcome
Prognostic awareness (PA) will be measured using the Chochinov Prognostic Awareness Scale. This scale classifies patients into three categories of awareness: full, limited, or no awareness.
Conditions Studied
Interventions
- BEHAVIORAL surveys and cognitive tests
Study Locations (1)
New York
- Memoral Sloan Kettering Cancer Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 95 participants |
| Start Date | 2013-12 |
| Est. Completion | 2018-10-30 |
What the finished NCT02023346 record still lists
NCT02023346 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 95 participants, a relatively small participant target, roughly in line with the 90-participant average among 40 other Malignant Glioma trials with a reported enrollment target.
The record links to 1 condition, with Malignant Glioma appearing as the primary indexed condition, and to 1 intervention - of which surveys and cognitive tests is the first listed.
NCT02023346 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT02023346 about?
NCT02023346 is a clinical study titled "Prognostic Awareness and Patient-Physician Communication in Malignant Glioma". The purpose of this study is to learn more about the understanding patients with brain tumors have of their disease and their communication with their physician. Ultimately, we hope to use these findings to improve communication between patients and their doctors.
What is the current status of trial NCT02023346?
This trial is currently completed. The enrollment target is 95 participants. The study started on 2013-12. Estimated completion is 2018-10-30.
What conditions does trial NCT02023346 study?
This clinical trial studies the following conditions: Malignant Glioma.
What interventions are being tested in trial NCT02023346?
The interventions under investigation include: surveys and cognitive tests (BEHAVIORAL).
Who is sponsoring clinical trial NCT02023346?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02023346 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Malignant Glioma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02023346's enrollment target sits among peer trials
95 7th of 40 higher than 34 of 40 other Malignant Glioma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Malignant Glioma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Mapping of Electrical Properties in the Brain
RECRUITING
-
CARv3-TEAM-E T Cells in Glioblastoma
RECRUITING · Phase 1
-
Serial Advanced Magnetic Resonance Imaging Scan for Guidance of Personalized Adaptive Radiotherapy for High Grade Glioma
RECRUITING
-
Fitness and Nutrition in Glioma
RECRUITING · NA
-
Panitumumab-IRDye800 in Diagnosing Participants With Malignant Glioma Undergoing Surgery
RECRUITING · Phase 1
-
A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03339128 · 95 participants · Phase 2
Study to Explore the Therapeutic Effect of Eluxadoline in Treating Irritable Bowel Syndrome With Diarrhea in Children
- NCT03509961 · 95 participants · Phase 2
The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and Young Adults With B-ALL
- NCT03694756 · 95 participants · NA
TMEM-MRI: A Pilot Feasibility Study of MRI for Imaging of TMEM in Patients With Operable Breast Cancer
- NCT04206215 · 95 participants · NA
Noninvasive Brain Stimulation for Treating Carpal Tunnel Syndrome
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia